149 related articles for article (PubMed ID: 28718236)
1. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release.
Hameed M; Khan K; Salman S; Mehmood N
J Ayub Med Coll Abbottabad; 2017; 29(2):225-229. PubMed ID: 28718236
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus.
Bhansali A; Masoodi SR
J Assoc Physicians India; 2005 May; 53():441-5. PubMed ID: 16124352
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
Derosa G; D'Angelo A; Romano D; Maffioli P
Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
[TBL] [Abstract][Full Text] [Related]
4. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
Aggarwal N; Singla A; Mathieu C; Montanya E; Pfeiffer AFH; Johnsson E; Zhao J; Iqbal N; Bailey C
Diabetes Obes Metab; 2018 Feb; 20(2):463-467. PubMed ID: 28857388
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
[TBL] [Abstract][Full Text] [Related]
6. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
Fujioka K; Pans M; Joyal S
Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
Timmins P; Donahue S; Meeker J; Marathe P
Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.
Schwartz S; Fonseca V; Berner B; Cramer M; Chiang YK; Lewin A
Diabetes Care; 2006 Apr; 29(4):759-64. PubMed ID: 16567811
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.
Ji L; Liu J; Yang J; Li Y; Liang L; Zhu D; Li Q; Ma T; Xu H; Yang Y; Zeng J; Feng B; Qu S; Li Y; Ma L; Lin S; Wang J; Li W; Song W; Li X; Luo Y; Xi S; Lin M; Liu Y; Liang Z
Diabetes Obes Metab; 2018 Apr; 20(4):1006-1013. PubMed ID: 29227571
[TBL] [Abstract][Full Text] [Related]
11. Metformin extended release: metformin gastric retention, metformin GR, metformin XR.
Drugs R D; 2005; 6(5):316-9. PubMed ID: 16128603
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
13. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
Buse JB; DeFronzo RA; Rosenstock J; Kim T; Burns C; Skare S; Baron A; Fineman M
Diabetes Care; 2016 Feb; 39(2):198-205. PubMed ID: 26285584
[TBL] [Abstract][Full Text] [Related]
14. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
[TBL] [Abstract][Full Text] [Related]
15. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
Perez A; Zhao Z; Jacks R; Spanheimer R
Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
[TBL] [Abstract][Full Text] [Related]
17. Overview of metformin: special focus on metformin extended release.
Ali S; Fonseca V
Expert Opin Pharmacother; 2012 Aug; 13(12):1797-805. PubMed ID: 22775758
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia.
Kim CH; Han KA; Oh HJ; Tan KE; Sothiratnam R; Tjokroprawiro A; Klein M
J Diabetes; 2012 Dec; 4(4):395-406. PubMed ID: 22742083
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
